Stanford Cancer Institute earned the NCI Comprehensive Cancer Center designation, becoming the eighth institution in California to earn this highest level of recognition.
OmniSeq, a subsidiary of Roswell Park Cancer Institute, received New York State Clinical Laboratory Evaluation Program approval for its OmniSeq Comprehensive panel, a 144 gene, pan-cancer, next-generation sequencing tumor profiling diagnostic panel to guide oncology treatment decision-making. “OmniSeq is proud to receive New York State CLEP approval for OmniSeq Comprehensive. CLEP is the highest standard […]
Novartis entered into a collaboration and license agreement with Xencor Inc. to develop and commercialize novel therapeutics, including XmAb 14045 for acute myeloid leukemia, and XmAb 13676 for B-cell malignancies. Both are expected to begin development this year. Under the terms of the agreement, the parties will collaborate and share development costs for the worldwide […]
Hetero launched a biosimilar of bevacizumab in India for the treatment of metastatic colorectal cancer under the brand name Cizumab. The product has been approved by the drug controller general of India and has been recommended as a first-line treatment for mCRC. The product will be made available to patients in a single dose vial […]
FDA granted Fast Track Designation to ets-family inhibitor TK216 in Ewing sarcoma patients that have relapsed or are refractory to standard of care therapy. Oncternal Therapeutics Inc., the drug’s sponsor, is in the process of initiating a first-in-human phase I trial in relapsed or refractory Ewing sarcoma. TK216 is a first-in-class small molecule that inhibits […]
FDA approved Epclusa to treat adult patients with chronic hepatitis C virus both with and without cirrhosis. For patients with moderate to severe cirrhosis, Epclusa is approved for use in combination with the drug ribavirin.
STEVEN PAUL was elected chairman of the Foundation for the National Institutes of Health. Paul succeeds Charles Sanders, who has served as chairman since 1997 and will remain a member of the board. In addition, Thomas Insel and Paul Stoffels were elected as new board members. Paul is president and CEO at Voyager Therapeutics, Inc., […]
HAAKON RAGDE was named the 2016 Honorary Member of the American Society for Radiation Oncology, the highest honor ASTRO bestows on members in disciplines other than radiation oncology, radiobiology or radiation physics.
THE WISTAR INSTITUTE has entered into an agreement with the Gene Editing Institute at Christiana Care’s Helen F. Graham Cancer Center & Research Institute, expanding their previous partnership established in 2011. The Gene Editing Institute will be integrated into Wistar’s Molecular Screening Facility. The Gene Editing Institute will retain its management structure and will remain […]
MOUNT SINAI HEALTH SYSTEM and Valley Health System plan to form a partnership that will enable Valley to access Mount Sinai’s roster of clinical trials, as well as develop new programs and services. In December 2015, Valley and Mount Sinai announced plans to collaborate on clinical programs, research and educational offerings. Mount Sinai and Valley […]
